அமெரிக்கன் புற்றுநோய் சமூகம் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from அமெரிக்கன் புற்றுநோய் சமூகம் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In அமெரிக்கன் புற்றுநோய் சமூகம் இன்க் Today - Breaking & Trending Today

Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer


Share this article
Share this article
SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.
The newly announced data are from a phase 2 trial evaluating pelareorep in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in pancreatic adenocarcinoma patients who progressed after first-line treatment. Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, which is mediated through the complementary immunotherapeutic effects of the two agents. ....

United States , Devalingam Mahalingam , Jon Patton , Timothy Mccarthy , Thomas Heineman , Oncolytics Biotech Inc , American Society Of Clinical Oncology , Company Contact , American Cancer Society Inc , Global Head Of Clinical Development , Northwestern University Feinberg School Of Medicine , Oncolytics Biotech , Securities Exchange , Roberth Lurie Comprehensive Cancer Center , Northwestern University , American Cancer Society , Clinical Oncology , Annual Meeting , Principal Investigator , Associate Professor , Northwestern University Feinberg School , Comprehensive Cancer Center , Global Head , Clinical Development , Colorectal Cancer , Pancreatic Cancer ,

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights


Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
News provided by
Share this article
- Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments
- On track to report clinical biomarker and safety data in breast cancer in 2021
- Strong financial foundation with approximately $50 million in cash on hand and cash runway to H2 2022
- Management hosting conference call and webcast today at 8:30 am ET
SAN DIEGO and CALGARY, AB, March 5, 2021 /PRNewswire/ Oncolytics Biotech
® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter and year ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. ....

United States , United Kingdom , Matt Coffey , Oncolytic Reovirus Pelareorep , Timothy Mccarthy , Merck Kgaa Darmstadt , Oncolytics Biotech Inc , American Society Of Clinical Oncology , Company Contact , Ohio State University Comprehensive Cancer Center , Rutgers Cancer Institute Of New Jersey , Brain Tumor Charity , Society Of Neuro , Merck Kga , Breast Cancer Program , American Cancer Society , Hematologic Malignancies Program , American Cancer Society Inc , Cancer Research United Kingdom , Gastrointestinal Cancer Program , Oncolytics Biotech , Merck Kgaa , Securities Exchange , University Of Leeds , Chief Executive Officer , Demonstrating Pelareorep ,